The Bank of Nova Scotia

The Bank of Nova Scotia (NYSE: BNS) is a leading bank operating in the Americas. It offers a portfolio of banking advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets.

Key Highlights

• BNS reported only a 0.30% growth in total revenue to CAD 7.76 billion in Q3FY21 (ended July 31, 2021) compared to CAD 7.73 billion in Q3FY20.
• The company's assets, as of July 31, 2021, amounted to CAD 1.16 trillion.
• Net income for Q3FY21 was CAD 2.54 billion, increasing 94.94% from CAD 1.30 billion reported in Q3FY20, resulting from a reduction in the amount of provision for credit losses.
• On August 26, 2021, BNS stated that it made new updates to its mobile app, enhancing its customers' digital experience.
• On August 24, 2021, the company declared a dividend of CAD 0.90 per common share, payable on October 27, 2021, to shareholders of record on October 05, 2021.
• BNS' Efficiency Ratio for Q3FY21 was 52.1%, lower than the industry median of 56.4%.
• Stock is currently trading between its crucial short-term (50-day) as well as long-term (200-day) SMA support levels.
• Stock is currently at the higher end of the 52-week range of USD 40.16 to USD 68.02.

Technical Price Chart (as of August 26, 2021). Analysis by Kalkine

Conclusion: BNS' stock price increased 26.85% in the last nine months, and its RSI Index is 48.14. Considering the decent fundamentals, robust dividend yield, technical indicators, and current valuation, we recommend a "Watch" rating on the stock at the current price of USD 63.08, down 1.47% as of August 26, 2021, 1:52 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a commercial-stage biopharmaceutical company with a primary focus on the innovation and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for treating rare diseases.

Key Highlights

• SRPT reported a 19.46% growth in total revenue to USD 164.09 million in Q2FY21 (ended June 30, 2021) compared to USD 137.36 million in Q2FY20.
• Net loss for Q2FY21 was USD 81.41 million vs. a net loss of USD 150.82 million reported in Q2FY20, resulting from a USD 102.00 million gain recorded from the sale of the Priority Review Voucher completed in April 2021.
• The company exited the quarter with a cash balance (including short-term investments) of USD 1.73 billion and a total debt of USD 1.09 billion.
• On August 04, 2021, SRPT signed a license agreement for calpain 3 (CAPN-3), an investigational gene therapy candidate to treat Limb-girdle muscular dystrophy type 2A (LGMD2A). CAPN-3 is an Abigail Wexner Research Institute development.
• SRPT's EBITDA and operating margin for Q2FY21 were -97.0% and -102.1%, respectively.
• Stock is currently trading between its crucial short-term (50-day) as well as long-term (200-day) SMA support levels.
• Stock is currently at the lower end of the 52-week range of USD 65.30 to USD 181.83.

Technical Price Chart (as of August 26, 2021). Analysis by Kalkine

Conclusion: SRPT's stock price increased 19.50% in the last month, and its RSI Index is 57.69. Considering the meagre fundamentals, disappointing profit margins, other technical indicators, and current trading levels, we recommend an "Avoid" rating on the stock at the current price of USD 79.16, down 0.98% as of August 26, 2021, 1:56 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.